Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 study of BW-1010

Next Previous
Search
Trial Profile

Phase 1 study of BW-1010

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 01 Nov 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BW 1010 (Primary)
  • Indications Anthrax
  • Focus Adverse reactions

    • Most Recent Events

    • 01 Nov 2019 New trial record
    • 23 Oct 2019 According to a BlueWillow Biologics media release, the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application. This study is expected to begin enrollment this year and is being funded by the National Institute of Allergy and Infectious Diseases (NIAID), an institute within the National Institutes of Health (NIH).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top